Michal Vráblík - Concepedia

Author

Michal Vráblík

Also Known As

Anne Tybjærg-Hansen, Branislav Vohnout, Dragos Vinereanu, M Vrablik, M Vrablík, M Vráblík, M. VRABLIK, M. VRABLÍK, M. Vrablik, M. Vrabliks

347

Publications

7.8K

Citations

H-Index

Concepts

All Affiliations

Charles University Institute of Clinical and Experimental Medicine General University Hospital in Prague Medical University of Lodz National and Kapodistrian University of Athens

About

Michal Vráblík is an author at Charles University specializing in medicine, atherosclerosis, and metabolic syndrome.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	23	1.1K
2	Public Health	15	18	1.1K
3	Health Sciences	4	4	90
4	Biochemistry	3	3	84
5	Natural Sciences	2	2	61

Michal Vráblík

Publications

Citations

H-Index

Page 1

	Year	Citations
EU-Wi<i>d</i>e Cross-Section<i>a</i>l Obser<i>v</i>at<i>i</i>o<i>n</i>al Study of Lipid-Modifying Therapy Use in Se<i>c</i>ondary and Pr<i>i</i>mary Care: the DA VINCI study Kausik K. Ray, Bart Molemans, W. Marieke Schoonen, European Journal of Preventive Cardiology	2020	699
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients Paul M. Ridker, James H. Revkin, Pierre Amarenco, New England Journal of Medicine	2017	623
Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) Antonio J. Vallejo‐Vaz, Christophe Stevens, Alexander R.M. Lyons, The Lancet Family MedicineMetabolic SyndromeLipid DisorderCardiovascular DiseaseHealth Policy	2021	285
Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel Arrigo F.G. Cicero, Alessandro Colletti, Gani Bajraktari, Archives of Medical Science	2017	284
Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study Tycho R. Tromp, Merel L. Hartgers, G. Kees Hovingh, The Lancet Metabolic SyndromeLipid DisorderCardiovascular DiseaseGenetic EpidemiologyWorldwide Experience	2022	189
Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force Maurizio Averna, Maciej Banach, Éric Bruckert, Atherosclerosis Metabolic SyndromeCombination Lipid-modifying TherapyLipid DisorderCardiovascular DiseasePractical Guidance	2021	134
The impact of type of dietary protein, animal versus vegetable, in modifying cardiometabolic risk factors: A position paper from the International Lipid Expert Panel (ILEP) Fjolla Zhubi Bakija, Gani Bajraktari, Ibadete Bytyçi, Clinical Nutrition	2020	130
Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia Roberto Ferrari, Carlos Aguíar, Eduardo Alegría, European Heart Journal Supplements	2016	96
Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP) Maciej Banach, Peter E. Penson, Michal Vráblík, Pharmacological Research HypertensionOptimal UseHyperlipidemiaCoronary Artery DiseaseAcute Myocardial Infarction	2021	96
Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study Michal Vráblík, Bohumil Seifert, Alexander Parkhomenko, Atherosclerosis Metabolic SyndromeEastern EuropeNon-pharmacological InterventionPreventive MedicineLipid Disorder	2021	72

Page 1